Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FS-8002
- Development stage
- Phase 1
- Lead developer
- Changchun Huapu Biotechnology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
FS-8002 is a bifunctional antibody fusion protein designed to inhibit both transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF). It is being developed primarily for the treatment of advanced malignant solid neoplasms, including late-stage or refractory solid tumors. The drug acts as a dual inhibitor, targeting TGF-β and VEGF pathways, which are implicated in tumor progression, angiogenesis, and immune evasion. Preclinical studies have shown significant anti-tumor activity. The drug is currently in phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors[1][3][10].
- Brand names
- FS-8002FS8002FS 8002
- Other names
- FS 8002FS8002FS-8002
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TGFBR (TGF-beta receptor)
Beyond the preview
Go deeper on FS-8002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FS-8002.